A. Corbin

1.1k total citations · 1 hit paper
8 papers, 816 citations indexed

About

A. Corbin is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, A. Corbin has authored 8 papers receiving a total of 816 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Hematology, 4 papers in Genetics and 3 papers in Rheumatology. Recurrent topics in A. Corbin's work include Chronic Myeloid Leukemia Treatments (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Eosinophilic Disorders and Syndromes (3 papers). A. Corbin is often cited by papers focused on Chronic Myeloid Leukemia Treatments (5 papers), Chronic Lymphocytic Leukemia Research (4 papers) and Eosinophilic Disorders and Syndromes (3 papers). A. Corbin collaborates with scholars based in United States, United Kingdom and Germany. A. Corbin's co-authors include Brian Druker, Nicholas C.P. Cross, Harald Gschaidmeier, Claudia Schoch, Andreas Hochhaus, Sebastian Kreil, Paul La Rosée, Tanja Lahaye, Ute Berger and Rüdiger Hehlmann and has published in prestigious journals such as Blood, FEBS Letters and Antimicrobial Agents and Chemotherapy.

In The Last Decade

A. Corbin

8 papers receiving 802 citations

Hit Papers

Molecular and chromosomal mechanisms of resistance to ima... 2002 2026 2010 2018 2002 200 400 600

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Corbin United States 7 659 523 403 113 109 8 816
Franck E. Nicolini France 10 373 0.6× 240 0.5× 111 0.3× 122 1.1× 94 0.9× 24 512
Ph. Bernard France 8 303 0.5× 159 0.3× 112 0.3× 115 1.0× 67 0.6× 13 448
Shuhei Asada Japan 13 338 0.5× 158 0.3× 24 0.1× 270 2.4× 53 0.5× 26 570
Sandy W. Wong United States 20 583 0.9× 108 0.2× 29 0.1× 593 5.2× 683 6.3× 86 1.1k
S. Kurachi United States 17 348 0.5× 325 0.6× 12 0.0× 338 3.0× 66 0.6× 36 863
Ingbritt Åstrand‐Grundström Sweden 10 829 1.3× 223 0.4× 17 0.0× 343 3.0× 221 2.0× 12 1.3k
Sanjay Mohan United States 13 406 0.6× 199 0.4× 17 0.0× 333 2.9× 89 0.8× 63 685
Darryl Irwin Australia 13 123 0.2× 71 0.1× 34 0.1× 185 1.6× 213 2.0× 23 654
David Kan United States 13 148 0.2× 117 0.2× 83 0.2× 368 3.3× 322 3.0× 22 805
Papagudi Ganesan Subramanian India 15 338 0.5× 154 0.3× 37 0.1× 101 0.9× 139 1.3× 75 592

Countries citing papers authored by A. Corbin

Since Specialization
Citations

This map shows the geographic impact of A. Corbin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Corbin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Corbin more than expected).

Fields of papers citing papers by A. Corbin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Corbin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Corbin. The network helps show where A. Corbin may publish in the future.

Co-authorship network of co-authors of A. Corbin

This figure shows the co-authorship network connecting the top 25 collaborators of A. Corbin. A scholar is included among the top collaborators of A. Corbin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Corbin. A. Corbin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Brown, Ashley N., James J. McSharry, Jonathan Adams, et al.. (2011). Pharmacodynamic Analysis of a Serine Protease Inhibitor, MK-4519, against Hepatitis C Virus Using a NovelIn VitroPharmacodynamic System. Antimicrobial Agents and Chemotherapy. 56(3). 1170–1181. 9 indexed citations
2.
MacPartlin, Mary, Thomas O’Hare, Thomas G.P. Bumm, et al.. (2006). Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib.. Blood. 108(11). 4796–4796. 2 indexed citations
3.
Chuah, Charles, David Barnes, Marwan Kwok, et al.. (2005). Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells. Leukemia. 19(11). 1896–1904. 42 indexed citations
4.
Crossman, Lucy C., Thomas O’Hare, Thoralf Lange, et al.. (2005). A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib. Leukemia. 19(11). 1859–1862. 15 indexed citations
5.
Großmann, Arndt, Kathryn S. Kolibaba, Stephanie G. Willis, et al.. (2004). Catalytic domains of tyrosine kinases determine the phosphorylation sites within c‐Cbl. FEBS Letters. 577(3). 555–562. 13 indexed citations
6.
Hochhaus, Andreas, Sebastian Kreil, A. Corbin, et al.. (2002). Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 16(11). 2190–2196. 675 indexed citations breakdown →
7.
Kreil, Sebastian, Martin Müller, Tanja Lahaye, et al.. (2001). Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy. ePrints Soton (University of Southampton). 16 indexed citations
8.
Assayag, Gérard, Christophe Vieu, J. Giérak, P. Sudraud, & A. Corbin. (1993). New characterization method of ion current-density profile based on damage distribution of Ga+ focused-ion beam implantation in GaAs. Journal of Vacuum Science & Technology B Microelectronics and Nanometer Structures Processing Measurement and Phenomena. 11(6). 2420–2426. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026